Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the
combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with
relapsed or refractory diffuse large B-cell lymphoma (DLBCL).